JP2015530971A5 - - Google Patents

Download PDF

Info

Publication number
JP2015530971A5
JP2015530971A5 JP2015520685A JP2015520685A JP2015530971A5 JP 2015530971 A5 JP2015530971 A5 JP 2015530971A5 JP 2015520685 A JP2015520685 A JP 2015520685A JP 2015520685 A JP2015520685 A JP 2015520685A JP 2015530971 A5 JP2015530971 A5 JP 2015530971A5
Authority
JP
Japan
Prior art keywords
seq
tau
amino acid
antibody
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015520685A
Other languages
English (en)
Japanese (ja)
Other versions
JP6345655B2 (ja
JP2015530971A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/049333 external-priority patent/WO2014008404A1/en
Publication of JP2015530971A publication Critical patent/JP2015530971A/ja
Publication of JP2015530971A5 publication Critical patent/JP2015530971A5/ja
Application granted granted Critical
Publication of JP6345655B2 publication Critical patent/JP6345655B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015520685A 2012-07-03 2013-07-03 タウに対する抗体 Expired - Fee Related JP6345655B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261667515P 2012-07-03 2012-07-03
US61/667,515 2012-07-03
US201261694989P 2012-08-30 2012-08-30
US61/694,989 2012-08-30
PCT/US2013/049333 WO2014008404A1 (en) 2012-07-03 2013-07-03 Antibodies to tau

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018098889A Division JP2018184398A (ja) 2012-07-03 2018-05-23 タウに対する抗体

Publications (3)

Publication Number Publication Date
JP2015530971A JP2015530971A (ja) 2015-10-29
JP2015530971A5 true JP2015530971A5 (enExample) 2016-08-18
JP6345655B2 JP6345655B2 (ja) 2018-06-20

Family

ID=49882495

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015520685A Expired - Fee Related JP6345655B2 (ja) 2012-07-03 2013-07-03 タウに対する抗体
JP2018098889A Pending JP2018184398A (ja) 2012-07-03 2018-05-23 タウに対する抗体
JP2020070416A Pending JP2020125310A (ja) 2012-07-03 2020-04-09 タウに対する抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018098889A Pending JP2018184398A (ja) 2012-07-03 2018-05-23 タウに対する抗体
JP2020070416A Pending JP2020125310A (ja) 2012-07-03 2020-04-09 タウに対する抗体

Country Status (17)

Country Link
US (2) US9834596B2 (enExample)
EP (2) EP2870176A4 (enExample)
JP (3) JP6345655B2 (enExample)
KR (3) KR20150036346A (enExample)
CN (2) CN108623682A (enExample)
AU (3) AU2013286680B2 (enExample)
BR (1) BR112014033116B1 (enExample)
CA (1) CA2877397A1 (enExample)
HK (1) HK1209768A1 (enExample)
IL (3) IL236409B (enExample)
IN (1) IN2015KN00007A (enExample)
MX (2) MX359555B (enExample)
MY (1) MY171473A (enExample)
NZ (2) NZ703423A (enExample)
RU (2) RU2018132044A (enExample)
SG (3) SG10201708959WA (enExample)
WO (1) WO2014008404A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201708959WA (en) 2012-07-03 2017-11-29 Univ Washington Antibodies to tau
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
BR112016029579A2 (pt) * 2014-06-26 2017-08-22 Janssen Vaccines & Prevention Bv anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
TWI734975B (zh) * 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
WO2016054247A1 (en) 2014-09-30 2016-04-07 Washington University Tau kinetic measurements
MA41451A (fr) * 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
NZ775762A (en) 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
US10344081B2 (en) 2015-07-06 2019-07-09 Ucb Biopharma Sprl Tau-binding antibodies
WO2017005734A1 (en) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
WO2017027691A1 (en) * 2015-08-13 2017-02-16 New York University Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
CN109580954B (zh) * 2015-09-16 2022-03-22 北京九强生物技术股份有限公司 一种人肌钙蛋白i的超敏定量测定试剂盒及其检测方法
MY198194A (en) 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
MX2018013386A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
PH12018502613B1 (en) 2016-07-12 2023-02-01 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
CA3032692A1 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination antibody therapy for the treatment of neurodegenerative diseases
BR112018014281A2 (pt) 2016-11-15 2018-12-18 H Lundbeck As agentes, usos e métodos para o tratamento da sinucleinopatia
UA128383C2 (uk) 2016-12-07 2024-07-03 Дженентек, Інк. Антитіло до тау-білка та спосіб його застосування
MX2019006330A (es) 2016-12-07 2019-09-26 Genentech Inc Anticuerpos anti-tau y metodos de uso.
CN106749658B (zh) * 2016-12-15 2019-11-12 北京师范大学 抑制Tau蛋白聚集的抗体型分子伴侣
EP3555127B1 (en) 2016-12-16 2024-12-18 H. Lundbeck A/S Agents, uses and methods
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
WO2018165015A1 (en) * 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
WO2019180261A1 (en) 2018-03-23 2019-09-26 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
US11629175B2 (en) 2018-04-27 2023-04-18 Ecole Polytechnique Federale De Lausanne (Epfl) Method for preparing PHFS-like Tau aggregates
CA3107788A1 (en) 2018-07-31 2020-02-06 Eli Lilly And Company Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation
CN109613242A (zh) * 2018-11-01 2019-04-12 深圳天辰医疗科技有限公司 一种肌酸激酶同工酶检测试剂盒及其制备方法
JP7630834B2 (ja) 2019-03-03 2025-02-18 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
CN120648640A (zh) * 2019-03-18 2025-09-16 瑞泽恩制药公司 用于鉴定tau接种或聚集的基因修饰因子的CRISPR/Cas筛选平台
EP3769090B1 (en) * 2019-03-18 2023-11-15 Regeneron Pharmaceuticals, Inc. Crispr/cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation
CN110055280A (zh) * 2019-03-19 2019-07-26 深圳大学 一种稳定表达mCherry-tau的细胞系及其构建方法与应用
EP4001305A4 (en) * 2019-07-15 2022-10-12 Adel Inc. ANTI-TAU ANTIBODIES AND ITS USE
KR20220062287A (ko) * 2019-08-13 2022-05-16 워싱턴 유니버시티 Mtbr 타우 아이소폼 검출 방법 및 이의 용도
AU2020364157A1 (en) 2019-10-09 2022-04-14 Bluerock Therapeutics Lp Cells with sustained transgene expression
CA3159964A1 (en) * 2019-12-04 2021-06-10 Ac Immune Sa Novel molecules for therapy and diagnosis
US20220145363A1 (en) * 2020-11-09 2022-05-12 Meso Scale Technologies, Llc. Methods and kits for detecting tau
WO2022144406A1 (en) 2020-12-29 2022-07-07 Neurimmune Ag Human anti-tau antibodies
EP4314048A1 (en) 2021-03-26 2024-02-07 Janssen Biotech, Inc. Anti-tau antibodies and uses thereof
JP2024513172A (ja) 2021-03-26 2024-03-22 ヤンセン バイオテツク，インコーポレーテツド 対らせん状細線維タウに対するヒト化抗体及びその使用
CL2021001380A1 (es) 2021-05-26 2022-01-14 Corporacion Centro Int De Biomedicina Icc Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias.
WO2024044637A2 (en) * 2022-08-23 2024-02-29 Washington University Anti-tau mtbr antibodies and methods to detect cleaved fragments of tau and uses thereof
CN121773336A (zh) * 2023-07-20 2026-03-31 拉亚·蒙托柳加亚 P-tau免疫测定
WO2025216325A1 (ja) * 2024-04-11 2025-10-16 国立大学法人東京大学 生体から脳間質液中のタウシードを回収する方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01163661A (ja) 1987-10-02 1989-06-27 E I Du Pont De Nemours & Co ＩｇＧ捕捉抗体および多重単クローン性抗体検出系を用いたイムノアツセイ
EP0600951A4 (en) 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
US5733734A (en) 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
DE69220503T2 (de) 1991-10-25 1998-02-05 Innogenetics Nv Monoklonale Antikörper gegen das mikrotubulusassoziierte Protein Tau.
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
DK0618968T3 (da) 1991-12-06 2000-04-10 Max Planck Gesellschaft Midler til diagnostisering og behandling af Alzheimer's sygdom
JPH06239899A (ja) 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
WO1996004309A1 (en) 1994-07-29 1996-02-15 Innogenetics N.V. Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
US20020086009A1 (en) 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
AU5508798A (en) 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
US6797478B1 (en) 1998-03-05 2004-09-28 University Of Cincinnati Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies
RU2238947C2 (ru) * 1998-07-14 2004-10-27 Янссен Фармацевтика Н.В. Нейротрофический фактор роста человека (эновин), кодирующая его выделенная молекула нуклеиновой кислоты, вектор (варианты), фармацевтическая композиция (варианты), антитело, способ обнаружения фактора роста, набор, способ идентификации агониста или антагониста (варианты)
BR9913112A (pt) 1998-09-08 2001-05-08 Innogenetics Nv Tau como um marcador para dano inicial de cns
US6495376B1 (en) * 1999-02-18 2002-12-17 Beth Israel Deaconess Medical Center Methods and compositions for regulating protein-protein interactions
US6589746B1 (en) 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
US20020182660A1 (en) 2000-02-18 2002-12-05 Fong Kei-Lai L. N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43)
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
EP3960855A1 (en) 2001-12-28 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing proteins
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
US20060167227A1 (en) 2002-07-12 2006-07-27 Axon Neuroscience Forschungs-Und Entwicklungs Gmbh Truncated tau proteins
JP4393382B2 (ja) 2002-08-14 2010-01-06 三菱化学株式会社 中枢性タウ蛋白質特異的抗体
FI20030652A0 (fi) 2003-04-30 2003-04-30 Susann Eriksson Parannettu immunomääritys
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
CA2598321A1 (en) 2005-02-19 2006-08-24 Peoplebio, Inc. Method for differentially detecting multimeric form from monomeric form of multimer-forming polypeptides
WO2007019273A2 (en) 2005-08-04 2007-02-15 Albert Einstein College Of Medicine Of Yeshiva University Phosphorylation of tau by abl
ES2321996B1 (es) 2006-01-26 2010-03-05 Consejo Superior Investig. Cientificas Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias.
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
MX2010011209A (es) 2008-04-24 2010-11-12 Squibb Bristol Myers Co Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer.
CN101307108B (zh) 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
ES2645692T3 (es) * 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
WO2010096751A1 (en) 2009-02-23 2010-08-26 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating a disease mediated by soluble oligomeric amyloid beta
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
WO2010129674A2 (en) 2009-05-05 2010-11-11 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
CN106390107B (zh) * 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
JP2013500326A (ja) * 2009-07-30 2013-01-07 ファイザー バクシーンズ エルエルシー 抗原性タウペプチドおよびその使用
AU2010286501B2 (en) 2009-08-28 2015-06-11 The Board Of Regents Of The University Of Texas System Antibodies that bind Tau oligomers
AU2010291933B2 (en) * 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
CN102549438B (zh) 2009-09-24 2014-10-29 国家健康与医学研究院 Fkbp52-tau相互作用作为新颖治疗靶点用于治疗涉及tau机能失调的神经障碍
WO2011109112A2 (en) 2010-03-05 2011-09-09 Albert Einstein College Of Medicine Of Yeshiva University Method of detecting tau protein and tau fragments in serum
MY164376A (en) * 2010-10-07 2017-12-15 Univ Leuven Kath Phosphospecific antibodies recognizing tau
AU2013205313B2 (en) 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
CA2813493C (en) * 2010-10-11 2019-07-09 University Of Zurich Human anti-tau antibodies
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
EP2701743A4 (en) 2011-04-27 2015-08-19 Univ Northwestern FOR PATHOLOGICAL TAU-DIMERE AND PREAFIBRILLARY PATHOLOGICAL TAU-OLIGOMER SELECTIVE ANTIBODIES AND THEIR USES IN THE APPLICATION, DIAGNOSIS AND MONITORING OF TAUOPATHIES
US20120321594A1 (en) 2011-05-06 2012-12-20 New York University Methods of controlling axon or dendrite development of neuronal cells
JP6457263B2 (ja) 2011-05-20 2019-01-23 オリゴメリックス インコーポレイテッド タウプロテアーゼ組成物および使用方法
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
US9926353B2 (en) 2011-07-19 2018-03-27 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
ME03008B (me) 2011-09-19 2018-10-20 Axon Neuroscience Se Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
KR101981351B1 (ko) 2011-10-07 2019-09-02 에이씨 이뮨 에스.에이. 타우를 인식하는 포스포특이적 항체
US20140294724A1 (en) 2011-10-24 2014-10-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
MX350311B (es) 2011-12-20 2017-09-01 Janssen Biotech Inc Anticuerpos anti-phf-tau y sus usos.
RU2644242C2 (ru) 2012-04-05 2018-02-08 Ац Иммуне С.А. Гуманизированное тау-антитело
WO2013177104A2 (en) 2012-05-21 2013-11-28 Felder Mitchell S Treatment for tauopathies
PL2857039T3 (pl) 2012-05-31 2020-05-18 Osaka City University Środek terapeutyczny lub środek profilaktyczny na otępienie
SG10201708959WA (en) 2012-07-03 2017-11-29 Univ Washington Antibodies to tau
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
EP2887955B1 (en) 2012-08-21 2020-08-19 Institute for Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
EP2906596B1 (en) 2012-10-12 2023-12-27 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9910048B2 (en) 2012-12-03 2018-03-06 Washington University Method for detection of aggregates in biological samples
US8921150B2 (en) 2012-12-06 2014-12-30 Taiwan Semiconductor Manufacturing Co., Ltd. Process to achieve contact protrusion for single damascene via
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
CA2896066C (en) 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
WO2014096321A1 (en) 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
WO2014159244A2 (en) 2013-03-14 2014-10-02 Merck Patent Gmbh O-GlcNAc TAU ANTIBODY AND USE THEREOF
WO2014150877A2 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
EP2968548B1 (en) 2013-03-15 2020-09-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體

Similar Documents

Publication Publication Date Title
JP2015530971A5 (enExample)
RU2015103228A (ru) Антитела против тау
JP2014526898A5 (enExample)
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
RU2016100892A (ru) Антитела против tweakr и их применение
JP2010526028A5 (enExample)
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
FI3332006T3 (fi) Uusia anti-PD-L1-vasta-aineita
JP2021500916A5 (enExample)
JP2013538057A5 (enExample)
JP2017535257A5 (enExample)
JP2015535828A5 (enExample)
JP2013500941A5 (enExample)
HRP20251181T1 (hr) Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene
JP2014511179A5 (enExample)
JP2016508496A5 (enExample)
JP2013506428A5 (enExample)
HRP20230844T1 (hr) Anti-cd3 antitijela, bispecifične molekule koje vežu antigen koji veže cd3 i cd20, i njihove upotrebe
RU2017145653A (ru) Средства, пути применения и способы лечения синуклеопатии
JP2018520668A5 (enExample)
FI3826667T3 (fi) Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi
JP2016509585A5 (enExample)
JP2015531768A5 (enExample)
JP2016501881A (ja) 血液脳関門（ｂｂｂ）を透過する二重特異性結合タンパク質
JP2017512838A5 (enExample)